BioMarin's Kuvan is tentatively given the thumbs up in Europe.
The FDA makes Eli Lilly wait for word on a lead drug.
Its diabetes franchise is about to get bigger.
The credit rating agency frowns on European pharmaceuticals.
The company's potential hepatitis C compound proves effective with fewer dosages.
Early data on its new hepatitis C compound looks good -- for now.
The pharmaceutical pledges public reports of its dealings with doctors.
Sanofi-Aventis finally wins a bidding war for a sought-after prize.
Bristol and Icahn both go hostile toward each other.
Vertex raises cash again by diluting itself.
Looking at legislative efforts to boost the biotech industry.
Its bid might not be going higher but it isn't going away either.
There's a small consolation prize in this rejection from the FDA.
It unveils a brand name, a partnership, and new data for its lead drug.
A European partner for the developer's angina drug could help rake in sales.
Increased FDA scrutiny may motivate the pharmaceutical's new drug-safety site.
Your potential acquisition isn't interested? Go for the hostile takeover!
Allergan's muscle relaxant Botox performs well in two studies.
The drugmaker charts a different course for its future.
ImClone rejects Bristol’s offer, but likely isn’t done dealing with it yet.